ArticleJournal of clinical medicine2021

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study.

Konrad Rejdak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.